MedPath

Using a New Human Milk Fortifier to Optimize Feeding

Not Applicable
Completed
Conditions
Preterm Infant
Growth
Interventions
Dietary Supplement: A new human milk fortifier
Registration Number
NCT04283799
Lead Sponsor
Children's Hospital of Fudan University
Brief Summary

This study aims to compare the safety and efficacy of a new HMF and those of other HMF used before in very preterm infants.

Detailed Description

Infants with fortified human milk feeding have the same rate of growth, lower incidence of nosocomial infections and feeding intolerance compared to those with formula feeding during hospitalization. However, the currently human milk fortifiers (HMF) have some nutritional components defects to meet the needs of very preterm infants. New HMF provide higher protein and fat, which are safe and well tolerate to use in preterm infants. Study on safety and efficacy of the new HMF is insufficient in Chinese preterm infant population. Our aims are to compare the safety and efficacy of a new HMF and other HMF used before in very preterm infants. Very low preterm infants with birth weights of 1000-1499g and gestational age 28+0 weeks to 31 + 6 weeks are included. Infants feeding with new HMF are in the experimental group. Infants feeding with other HMF are in the control group, a historically control group. Physical growth, nutritional indexes, incidence of feeding intolerance, and time to achieve full enteral feeding are compared between the two groups.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
276
Inclusion Criteria
  • Infants with gestational age between 28+0 weeks to 31+6 weeks, and 1000g≤ birth weight<1500g;
  • Delivered in the study centers or transfer to the study centers within 24 hours after birth;
  • Own mother's milk or human milk bank were available;
  • Only one of the twins is selected in this study;
  • Informed consent has been obtained.
Exclusion Criteria
  • Severe congenital malformations, severe asphyxia, intracranial hemorrhage and other diseases;
  • Small for gestational age infants (birth weight below the 10th percentile of the reference, Fenton premature infant growth chart (2013));
  • Enteral feeding is not tolerated in 14 days after birth;
  • Infants who have participated in other clinical trials within 1 month;
  • Other conditions not suitable for this study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
The new HMF groupA new human milk fortifierVery preterm infants tolerating 80mL/kg/day of enteral feeding for \>24 hours are started to receive the new human milk fortifier. Study procedure is from the first day of full-strength fortification feeding to the 21th days of that.
Primary Outcome Measures
NameTimeMethod
Growth velocity of weightDuring the procedure

Weight is tested daily using the same electronic weighing scale in the different study units. Growth velocity of weight is described in g/day.

Secondary Outcome Measures
NameTimeMethod
The change of serum potassiumThe first day of full-strength fortification feeding, the 21th days of full-strength fortification feeding.

Serum potassium is tested twice during the procedure. The change is the difference between baseline and after the intervention, described as mmol/L.

The change of serum phosphorusThe first day of full-strength fortification feeding, the 21th days of full-strength fortification feeding.

Serum phosphorus is tested twice during the procedure. The change is the difference between baseline and after the intervention, described as mmol/L.

Incidence of apneaDuring the period using HMF, an average of 30 days

Apnea is defined as premature infants with respiratory arrest of more than 20 seconds, accompanied by a slow heartbeat, purple or pale skin, and decreased muscle tone.

The changes of blood hemoglobinThe first day of full-strength fortification feeding, the 21th days of full-strength fortification feeding.

Blood hemoglobin is tested twice during the procedure. The change is the difference between baseline and after the intervention, described as g/dL.

The change of serum sodiumThe first day of full-strength fortification feeding, the 21th days of full-strength fortification feeding.

Serum sodium is tested twice during the procedure. The change is the difference between baseline and after the intervention, described as mmol/L.

Growth velocity of head circumferenceDuring the procedure

Head circumference is measured weekly using a nonelastic measuring tape placed over the largest circumference of the skull weekly. Growth velocity is described in cm/week.

Incidence of abnormal body temperatureDuring the period using HMF, an average of 30 days

Axillary temperature is tested by nurses using clinical electronic thermometers once every four hours. Either low body temperature ( \<35℃) or high body temperature ( \>37.5℃) is abnormal body temperature.

Incidence of feeding intoleranceFrom the start day of feeding to discharge,an average of 50 days

Feeding intolerance is defined as feeds being withheld for 24 hours or more due to concerns related to feeding.

Time to achieve full enteral feedingDuring the hospitalization,an average of 20 days

Infants tolerating 120mL/ kg/day of enteral feeding for \>24 hours are defined as full enteral feeding.

The change of serum albuminThe first day of full-strength fortification feeding, the 21th days of full-strength fortification feeding.

Serum albumin is tested twice during the procedure. The change is the difference between baseline and after the intervention, described as g/L.

The Change of triglyceride.The first day of full-strength fortification feeding, the 21th days of full-strength fortification feeding.

Triglyceride is tested twice during the procedure. The change is the difference between baseline and after the intervention, described as mmol/L.

Incidence of bronchopulmonary dysplasia (BPD)From birth to discharge, an average of 40 days

BPD is defined as oxygen requirement at 36 weeks' postconceptional age.

Incidence of sepsisFrom birth to discharge, an average of 30 days

Both culture confirmed sepsis and clinical sepsis are defined as sepsis in this study.

The change of serum proalbuminThe first day of full-strength fortification feeding, the 21th days of full-strength fortification feeding.

Serum proalbumin is tested twice during the procedure. The change is the difference between baseline and after the intervention, described as mg/L.

The changes of serum calciumThe first day of full-strength fortification feeding, the 21th days of full-strength fortification feeding.

Serum calcium is tested twice during the procedure. The change is the difference between baseline and after the intervention, described as mmol/L.

The change of serum alkaline phosphataseThe first day of full-strength fortification feeding, the 21th days of full-strength fortification feeding.

Serum alkaline phosphatase is tested twice during the procedure. The change is the difference between baseline and after the intervention, described as U/L.

The change of blood urea nitrogenThe first day of full-strength fortification feeding, the 21th days of full-strength fortification feeding.

Blood urea nitrogen is tested twice during the procedure. The change is the difference between baseline and after the intervention, described as mmol/L.

The changes of cholesterolThe first day of full-strength fortification feeding, the 21th days of full-strength fortification feeding.

Cholesterol is tested twice during the procedure. The change is the difference between baseline and after the intervention, described as mmol/L.

Incidence of abnormal heart rateDuring the period using HMF, an average of 30 days

Either heart rate increase (\>180/min) or decrease (\<90/min) is defined as abnormal heart rate.

Incidence of necrotizing enterocolitis (NEC)From birth to discharge, an average of 20 days

NEC is diagnosed according to the Bell's grade scale.

Incidence of retinopathy of prematurity (ROP)From birth to discharge, an average of 40 days

ROP is diagnosed by ophthalmologists according to fundus examination.

Trial Locations

Locations (7)

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

🇨🇳

Shanghai, Shanghai, China

Shanghai First Maternity and Infant Hosipital

🇨🇳

Shanghai, Shanghai, China

Shanghai Children's Medical Center

🇨🇳

Shanghai, Shanghai, China

Peking Union Medical College Hospital

🇨🇳

Peking, Beijing, China

Nanjing Maternal and Child Health Hospital

🇨🇳

Nanjing, Jiangsu, China

Children's Hospital of Shanghai Jiao Tong University

🇨🇳

Shanghai, Shanghai, China

Children's Hospital of Fudan University

🇨🇳

Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath